Hedge fund billionaire Steven A. Cohen’s investment firm reported Wednesday a 5.3% stake in the biotech firm Chimerix Inc., just days after its shares plunged about 80% in one day after reporting an unsuccessful late-stage drug trial.
Mr. Cohen’s Point72 Asset Management, previously known as SAC Capital Advisors, reported its holdings on a regulatory form designated for passive investors.